Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trendlines Group ( (SG:42T) ) just unveiled an announcement.
Vensica Medical, a clinical-stage urology company incubated by Trendlines Group, has received U.S. FDA clearance of its Investigational New Drug application to begin a Phase 2 trial of ViXe, a needle-free, ultrasound-based delivery system for Xeomin in overactive bladder. Trendlines holds about 9% of Vensica, which is backed by strategic investors including Merz Pharma, Laborie and Israel Biotech Fund, underscoring Trendlines’ role in advancing innovative medtech assets.
The Phase 2 study will enroll roughly 210 patients across the U.S. and Europe and has triggered a contractual milestone payment from Vensica’s strategic partners, reinforcing the commercial traction of the platform. By aiming to replace invasive botulinum toxin injections with a non‑invasive, needle‑free approach, ViXe targets improved patient acceptance and could materially shift the standard of care for an estimated 33 million Americans living with overactive bladder, highlighting the growing maturity of Trendlines’ portfolio.
More about Trendlines Group
The Trendlines Group, listed in Singapore and on OTCQX, invests in and develops agrifood and medtech innovations, turning early-stage technologies into commercial businesses. Operating in Israel and Singapore, it combines capital, sector expertise and strategic partnerships to drive growth, promote sustainability and create long-term value for shareholders through its portfolio companies.
Average Trading Volume: 3,265,777
Technical Sentiment Signal: Buy
Current Market Cap: S$90.24M
For a thorough assessment of 42T stock, go to TipRanks’ Stock Analysis page.